세계 위 체류 약물전달 시스템 시장 : 유형별, 제형별, 유통 채널별, 지역별 분석(-2030년)

According to Stratistics MRC, the Global Gastro-retentive Drug Delivery Systems Market is accounted for $14.9 billion in 2023 and is expected to reach $33.1 billion by 2030 growing at a CAGR of 12.1% during the forecast period. The term "gastro-retentive drug delivery" refers to methods, formulations, production techniques, storage systems, and technologies used to deliver pharmaceutical compounds to the target location in the gastro-intestinal tract, to enhance the effectiveness and safety of a drug delivery system, principles relating to drug manufacturing, route of administration, site-specific targeting, metabolism, and toxicity are applied. The enhancement of mucosal protection by the gastro-retentive drug delivery method can be used to prevent and control the condition.

According to the article published by the University of Arizona, H.pylori infection is higher in developing countries than the developed countries. The incidence of new infections in developing countries is 3 to 10% of the population compared to 0.5% in developed economies.

Market Dynamics:

Driver:

Rising demand for gastro-retentive drugs

The market's growth has been accelerated by large pharmaceutical companies' efforts to improve gastro-retentive drug delivery systems, together with dose reductions due to improved bioavailability and an increase in the demand for drugs. Additionally, the market is greatly influenced by the well-established effectiveness of gastro-retentive drug delivery systems in treating various kinds of stomach disorders, including peptic ulcer and gastric ulcer, as well as an increase in the prevalence of H.pylori infection, which can lead to gastritis and gastric cancer which enabled the use of gastro-retentive drugs resulting in market expansion.

Restraint:

Decrease in Patient acceptance

The innovative nature of these new medicine delivery techniques may make them difficult for patients to accept. Additionally, patients may prefer traditional oral dosage forms especially for individuals who have difficulty swallowing or who prefer smaller-sized dosage forms. Moreover, ensuring consistent compliance is also challenging, as it relies on patients following specific administration instructions. Thus, some patients may find the size or characteristics of Gastro-retentive Drug Delivery Systems (GRDDS) less convenient by which the market gets significantly retrain.

Opportunity:

Technological advancements

The use of gastro-retentive drug delivery technology has proven to be an effective technique to control the dosage of a variety of pharmaceuticals while increasing bioavailability. Moreover, technology innovations that go beyond physical challenges like erratic stomach emptying timings and brief gastric residency times have led to improvements in controlled oral medicine administration systems in recent years. Additionally, once-GRDDS can improve therapeutic effectiveness and oral bioavailability by prolonging their duration in the upper GI tract. Hence, these advancements drive the market size.

Threat:

Risks associated while formulating

There are challenging obstacles to overcome when creating pharmacological formulations that can consistently stick to the gastrointestinal mucosa or float in the stomach while releasing the drug at a controlled rate. Moreover, it takes exact formulation methods and in-depth research to achieve this balance of adhesion, buoyancy, and controlled release. Additionally, the difficulty is increased further by the need to ensure the drug's stability in the gastrointestinal environment. Therefore, these difficulties frequently lead to longer development times and higher prices, which have an effect on market growth.

COVID-19 Impact

The market for gastro-retentive drug delivery systems (GRDDS) has been negatively impacted by the COVID-19 epidemic. Clinical trials and research for the development of GRDDS-based drugs were delayed while healthcare systems concentrated on fighting the virus. Additionally, access to medical facilities became restricted, which had an impact on the recruitment of patients for clinical trials and the uptake of innovative drug delivery methods. Moreover, economical limitations and supply chain interruptions have hampered the manufacture and distribution of GRDDS goods. Therefore, budgets for novel drug delivery methods were impacted as a result of the pandemic's increasing financial load on healthcare systems which gradually hampered the market growth.

The floating drug delivery system (FDDS) segment is expected to be the largest during the forecast period

The floating drug delivery system segment is estimated to hold the largest share. These are drug formulations that remain buoyant in the stomach for an extended period. Additionally, these methods allow medications to release gradually while floating on the gastric fluid, improving drug absorption and extending therapeutic benefits. Floating drug delivery system (FDDS) can reduce side effects, decrease dosage frequency, and increase drug absorption. Furthermore, they are particularly helpful for medications with small absorption windows and are used in the treatment of a variety of gastrointestinal ailments. Therefore, a cutting-edge method for improving medication delivery, FDDS ensures higher patient compliance and therapeutic effectiveness in gastro-retentive medicines thereby increasing the market expansion.

The microspheres segment is expected to have the highest CAGR during the forecast period

The microspheres segment is anticipated to have highest CAGR during the forecast period due to the use of small, spherical particles in medicine formulations to improve absorption of the medicament in the gastrointestinal tract. Additionally, these microspheres can contain medications for controlled release and are typically made of biocompatible substances. They provide advantages after consumption, including longer drug administration, decreased dosage frequency, and reduced side effects. GRDDS with microspheres is used to treat a variety of gastrointestinal illnesses, enhancing patient compliance and therapeutic results. Hence, this section shows an original pharmacological strategy for enhancing gastrointestinal system drug absorption and therapeutic efficacy by significantly driving the market.

Region with largest share:

Asia Pacific commanded the largest market share during the extrapolated period owing to due to their better drug absorption and patient compliance. Additionally, the Asia-Pacific region is spending money on medical research and infrastructure, which encourages innovation and market growth. Adoption of GRDDS is further fuelled by regulatory changes and the rise in chronic diseases. Therefore, pharmacies, researchers, and healthcare practitioners in the GRDDS industry have a lot of opportunities in this region.

Region with highest CAGR:

Europe is expected to witness highest CAGR over the projection period, owing to a major role in the advancement of GRDDS technology, placing a strong emphasis on both innovation and high-quality healthcare. Additionally, there is a need for better drug delivery methods due to the aging population in the area and the high prevalence of gastrointestinal illnesses. Moreover, in order to improve treatment outcomes, patient compliance, and quality of life, European healthcare systems encourage the development and deployment of GRDDS. Hence, stringent regulatory standards ensure product safety, making it a thriving market.

Key players in the market:

Some of the key players in the Gastro-retentive Drug Delivery Systems Market include: Ranbaxy, GlaxoSmithKline, Competition Deep Dive, Depomed, Pharmacia, Alcon, Inc., Lupin, Galanix, Sun Pharma and F. Hoffmann La Roche.

Key Developments:

In October 2023, Sun Pharmaceutical Industries Ltd announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for deuruxolitinib, an investigational oral selective inhibitor of Janus kinases, for the treatment of adults with moderate to severe alopecia areata.

In March 2023, Sun Pharmaceutical Industries Limited announced the successful completion of its acquisition of Concert Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company that is developing deuruxolitinib, a novel, deuterated, oral JAK1/2 inhibitor, for the potential treatment of adult patients with moderate to severe alopecia area.

Types Covered:

• Expandable Drug Delivery System
• Bioadhesive Drug Delivery System
• Floating Drug Delivery System
• High Density System
• Other Types

Dosage Forms Covered:

• Microspheres
• Tablets
• Capsule
• Other Dosage Forms

Distribution Channels Covered:

• Online Pharmacies
• Hospital Pharmacies
• Retail Pharmacies
• Other Distribution Channels

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Emerging Markets
• 3.7 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Gastro-retentive Drug Delivery Systems Market, By Type

• 5.1 Introduction
• 5.2 Expandable Drug Delivery System
• 5.3 Bioadhesive Drug Delivery System
• 5.4 Floating Drug Delivery System (FDDS)
• 5.5 High Density System
• 5.6 Other Types

6 Global Gastro-retentive Drug Delivery Systems Market, By Dosage Form

• 6.1 Introduction
• 6.2 Microspheres
• 6.3 Tablets
• 6.4 Capsule
• 6.5 Other Dosage Forms

7 Global Gastro-retentive Drug Delivery Systems Market, By Distribution Channel

• 7.1 Introduction
• 7.2 Online Pharmacies
• 7.3 Hospital Pharmacies
• 7.4 Retail Pharmacies
• 7.5 Other Distribution Channels

8 Global Gastro-retentive Drug Delivery Systems Market, By Geography

• 8.1 Introduction
• 8.2 North America
  • 8.2.1 US
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 Italy
  • 8.3.4 France
  • 8.3.5 Spain
  • 8.3.6 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 Japan
  • 8.4.2 China
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 New Zealand
  • 8.4.6 South Korea
  • 8.4.7 Rest of Asia Pacific
• 8.5 South America
  • 8.5.1 Argentina
  • 8.5.2 Brazil
  • 8.5.3 Chile
  • 8.5.4 Rest of South America
• 8.6 Middle East & Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 UAE
  • 8.6.3 Qatar
  • 8.6.4 South Africa
  • 8.6.5 Rest of Middle East & Africa

9 Key Developments

• 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 9.2 Acquisitions & Mergers
• 9.3 New Product Launch
• 9.4 Expansions
• 9.5 Other Key Strategies

10 Company Profiling

• 10.1 Ranbaxy
• 10.2 GlaxoSmithKline
• 10.3 Competition Deep Dive
• 10.4 Depomed
• 10.5 Pharmacia
• 10.6 Alcon, Inc.
• 10.7 Lupin
• 10.8 Galanix
• 10.9 Sun Pharma
• 10.10 F. Hoffmann La Roche